公开(公告)号：US20220220077A1

公开(公告)日：2022-07-14

申请号：US17606303

申请日：2020-05-19

Applicant: H. Lundbeck A/S

Inventor： Morten Jørgensen ,  Erhad Ascic ,  Martin Juhl ,  Klaus Gjervig Jensen ,  Ask Püschl ,  Benny Bang-Andersen

IPC: C07D221/08 ,  C07F9/576

Abstract: The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

公开(公告)号：US20200030319A1

公开(公告)日：2020-01-30

申请号：US16291865

申请日：2019-03-04

Applicant: H. Lundbeck A/S

Inventor： Connie Sanchez Morillo ,  Karina Krøjer Søby ,  Benny Bang-Andersen

IPC: A61K31/495 ,  A61K9/00 ,  A61K9/08 ,  A61K47/40

Abstract: A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone.

公开(公告)号：US20160083359A1

公开(公告)日：2016-03-24

申请号：US14948775

申请日：2015-11-23

Applicant: H. Lundbeck A/S

Inventor： Benny Bang-Andersen ,  André Faldt ,  Arne Mørk ,  Heidi Lopez De Diego ,  René Holm ,  Tine Bryan Stensbøl ,  Lone Munch Ringgard ,  Michael J. Mealy ,  Michael Harold Rock ,  Jørgen Brodersen ,  Morten Jørgensen ,  Nicholas Moore

IPC: C07D295/096

CPC classification number: A61K31/495 ,  A61K9/14 ,  A61P25/22 ,  C07D295/096 ,  Y10T428/2982

Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

Abstract translation: 1- [2-（2,4-二甲基苯基硫烷基）苯基]哌嗪显示出对SERT，5-HT3和5-HT1A的有效活性，并且可以用于治疗认知障碍，特别是抑郁症患者。

公开(公告)号：US09125910B2

公开(公告)日：2015-09-08

申请号：US14481000

申请日：2014-09-09

Applicant: H. Lundbeck A/S

Inventor： Benny Bang-Andersen ,  Arne Mork ,  Tine Bryan Stensbol ,  Andre Faldt

IPC: A61K31/495 ,  C07D295/096

CPC classification number: A61K31/495 ,  A61K9/14 ,  C07D295/096 ,  Y10T428/2982

Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD). The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

Abstract translation: 本公开涉及治疗选自阿尔茨海默氏病，认知障碍和注意缺陷多动障碍（ADHD）的疾病的方法。 该方法包括向有需要的患者施用治疗有效量的化合物I或其药学上可接受的盐，其中化合物I是1- [2-（2,4-二甲基苯基硫烷基） - 苯基]哌嗪。

公开(公告)号：US20140163043A1

公开(公告)日：2014-06-12

申请号：US13927678

申请日：2013-06-26

Applicant: H. Lundbeck A/S

Inventor： Thomas Ruhland ,  Garrick P. Smith ,  Benny Bang-Andersen ,  Ask Puschl ,  Ejner K. Moltzen ,  Kim Andersen

IPC: C07D295/096

CPC classification number: C07D295/145 ,  C07D211/20 ,  C07D211/70 ,  C07D243/08 ,  C07D295/033 ,  C07D295/096

Abstract: The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.

Abstract translation: 本发明提供由通式I表示的化合物，其中取代基在本申请中定义。 这些化合物可用于治疗情感障碍，包括抑郁症，焦虑症，包括一般焦虑症，惊恐障碍和强迫症。

公开(公告)号：US20180153881A1

公开(公告)日：2018-06-07

申请号：US15890006

申请日：2018-02-06

Applicant: H. Lundbeck A/S

Inventor： Connie Sanchez Morillo ,  Karina Krøjer Søby ,  Benny Bang-Andersen

IPC: A61K31/495 ,  A61K9/08 ,  A61K9/00

CPC classification number: A61K31/495 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/08 ,  A61K47/40 ,  A61K2300/00

Abstract: A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone.

公开(公告)号：US09125909B2

公开(公告)日：2015-09-08

申请号：US14326725

申请日：2014-07-09

Applicant: H. Lundbeck A/S

Inventor： Benny Bang-Andersen ,  Andre Faldt ,  Arne Mork ,  Heidi Lopez de Diego ,  Rene Holm ,  Tine Bryan Stensbol

IPC: A61K31/495 ,  C07D295/096

CPC classification number: A61K31/495 ,  A61K9/14 ,  C07D295/096 ,  Y10T428/2982

Abstract: This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form.

Abstract translation: 本公开涉及结晶形式的1- [2-（2,4-二甲基苯基硫烷基） - 苯基]哌嗪或其药学上可接受的盐。

公开(公告)号：US20150005318A1

公开(公告)日：2015-01-01

申请号：US14481000

申请日：2014-09-09

Applicant: H. Lundbeck A/S

Inventor： Benny Bang-Andersen ,  Arne Mork ,  Nicholas Moore ,  Tine Bryan Stensbol

IPC: A61K31/495

CPC classification number: A61K31/495 ,  A61K9/14 ,  C07D295/096 ,  Y10T428/2982

Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD). The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

Abstract translation: 本公开涉及治疗选自阿尔茨海默氏病，认知障碍和注意缺陷多动障碍（ADHD）的疾病的方法。 该方法包括向有需要的患者施用治疗有效量的化合物I或其药学上可接受的盐，其中化合物I是1- [2-（2,4-二甲基苯基硫烷基） - 苯基]哌嗪。

公开(公告)号：US20140377363A1

公开(公告)日：2014-12-25

申请号：US14480949

申请日：2014-09-09

Applicant: H. Lundbeck A/S

Inventor： Benny Bang-Andersen ,  Arne Mork ,  Nicholas Moore ,  Tine Bryan Stensbol

IPC: C07D295/096 ,  A61K31/495 ,  A61K9/14

CPC classification number: A61K31/495 ,  A61K9/14 ,  C07D295/096 ,  Y10T428/2982

Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

Abstract translation: 本公开涉及治疗选自情感障碍，抑郁症，重度抑郁障碍，焦虑症，一般焦虑症，社会焦虑症，强迫症，惊恐障碍和惊恐发作的疾病的方法。 该方法包括向有需要的患者施用治疗有效量的化合物I或其药学上可接受的盐，其中化合物I是1- [2-（2,4-二甲基苯基硫烷基） - 苯基]哌嗪。

公开(公告)号：US20180127389A1

公开(公告)日：2018-05-10

申请号：US15624417

申请日：2017-06-15

Applicant: H. Lundbeck A/S

Inventor： Thomas Ruhland ,  Garrick Paul Smith ,  Benny Bang-Andersen ,  Ask Puschl ,  Ejner Knud Moltzen ,  Kim Andersen

IPC: C07D295/145 ,  C07D295/033 ,  C07D211/20 ,  C07D243/08 ,  C07D211/70 ,  C07D295/096

CPC classification number: C07D295/145 ,  C07D211/20 ,  C07D211/70 ,  C07D243/08 ,  C07D295/033 ,  C07D295/096

Abstract: The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.